Clinical Trial Update: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial compares tucatinib versus placebo, both with trastuzumab and pertuzumab, in patients with metastatic HER2-positive breast cancer; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Perjeta (pertuzumab)
• Tukysa (tucatinib)

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: HER2 Positive Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING